benefit trial: isatuximab, lenalidomide, and dexamethasone /- bortezomib in newly diagnosed myeloma
Published 4 weeks ago • 202 plays • Length 4:13Download video MP4
Download video MP3
Similar videos
-
0:50
the safety and efficacy of isatuximab, bortezomib, lenalidomide, and dexamethasone in ndmm
-
1:52
analyzing isatuximab in quadruplet combinations in transplant-ineligible multiple myeloma
-
1:45
real-world safety & efficacy of isatuximab-pomalidomide-dexamethasone in r/r multiple myeloma
-
3:28
a phase ib trial of fixed-volume isatuximab infusion in newly-diagnosed multiple myeloma
-
3:05
recent advances in newly diagnosed multiple myeloma and the importance of patient perspectives
-
6:07
blood analysis in multiple myeloma
-
18:37
understanding multiple myeloma testing
-
4:36
what is isatuximab? and how does it compare with daratumumab?
-
2:09
fixed-volume isatuximab infusion in newly-diagnosed myeloma
-
2:32
the safety and efficacy of isatuximab for r/r myeloma: insights from icaria-mm, ikema & candor
-
4:01
choosing between isatuximab & daratumumab in multiple myeloma
-
2:25
multiple myeloma at ash 2015: new therapeutic opportunities
-
2:30
a new era of treatment for multiple myeloma
-
2:30
daratumumab and isatuximab in the treatment of multiple myeloma
-
1:49
current & possible uses of isatuximab in the treatment of myeloma and smoldering myeloma
-
2:22
myeloma xi trial: lenalidomide maintenance therapy for multiple myeloma
-
1:22
long-term follow-up results of tourmaline-mm2: ird vs pbo-rd in multiple myeloma
-
2:53
real-world data on upfront subcutaneous bortezomib-containing regimens for newly diagnosed myeloma
-
4:04
autograft purity indicates multiple myeloma treatment efficacy
-
1:29
managing toxicities associated with immunotherapy in multiple myeloma
-
1:26
insight-mm study update: treatment patterns in first and second-line multiple myeloma
-
1:08
safety and efficacy of iberdomide dexamethasone in patients with triple-class refractory myeloma